Literature DB >> 22374721

Post-translational modifications of p53 tumor suppressor: determinants of its functional targets.

N Taira1, K Yoshida.   

Abstract

Tumor suppressor p53 functions as a "guardian of the genome" to prevent cells from transformation. p53 is constitutively ubiquitinated and degradated in unstressed conditions, thereby suppressing the expression. However, cellular stimuli enable p53 to escape from the negative regulation, and then stably expressed p53 transactivates its target genes to induce cell cycle arrest, DNA repair, or apoptosis. Promoter preference of target genes is determined by modification status of p53. Because p53 has two critical roles in the decision of cell fate, stopping cell cycle to repair damaged DNA or induction of apoptotic cell death in response to DNA damage, elucidation of switching mechanisms on p53 functions is of particular importance. Here we review recent evidence how several post-translational modifications of p53 including methylation, phosphorylation, acetylation, and ubiquitination, affect the functions of p53 in response to cellular stress.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22374721     DOI: 10.14670/HH-27.437

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  22 in total

1.  Extensive post-translational modification of active and inactivated forms of endogenous p53.

Authors:  Caroline J DeHart; Jasdave S Chahal; S J Flint; David H Perlman
Journal:  Mol Cell Proteomics       Date:  2013-09-20       Impact factor: 5.911

Review 2.  Engagement of DYRK2 in proper control for cell division.

Authors:  Naoe Taira Nihira; Kiyotsugu Yoshida
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 3.  Caught in the cross fire: p53 in inflammation.

Authors:  Tomer Cooks; Curtis C Harris; Moshe Oren
Journal:  Carcinogenesis       Date:  2014-06-18       Impact factor: 4.944

Review 4.  Impact of EBV essential nuclear protein EBNA-3C on B-cell proliferation and apoptosis.

Authors:  Abhik Saha; Erle S Robertson
Journal:  Future Microbiol       Date:  2013-03       Impact factor: 3.165

5.  hSSB1 regulates both the stability and the transcriptional activity of p53.

Authors:  Shuangbing Xu; Yuanzhong Wu; Qiong Chen; Jingying Cao; Kaishun Hu; Jianjun Tang; Yi Sang; Fenju Lai; Li Wang; Ruhua Zhang; Sheng-Ping Li; Yi-Xin Zeng; Yuxin Yin; Tiebang Kang
Journal:  Cell Res       Date:  2012-11-27       Impact factor: 25.617

6.  Induction of amphiregulin by p53 promotes apoptosis via control of microRNA biogenesis in response to DNA damage.

Authors:  Naoe Taira; Tomoko Yamaguchi; Junko Kimura; Zheng-Guang Lu; Shinji Fukuda; Shigeki Higashiyama; Masaya Ono; Kiyotsugu Yoshida
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-30       Impact factor: 11.205

7.  NORE1A is a Ras senescence effector that controls the apoptotic/senescent balance of p53 via HIPK2.

Authors:  Howard Donninger; Diego F Calvisi; Thibaut Barnoud; Jennifer Clark; M Lee Schmidt; Michele D Vos; Geoffrey J Clark
Journal:  J Cell Biol       Date:  2015-03-16       Impact factor: 10.539

Review 8.  Molecular dynamic simulation insights into the normal state and restoration of p53 function.

Authors:  Ting Fu; Hanyi Min; Yong Xu; Jianzhong Chen; Guohui Li
Journal:  Int J Mol Sci       Date:  2012-08-03       Impact factor: 6.208

9.  Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models.

Authors:  Lays M Sobral; Lucas O Sousa; Ricardo D Coletta; Hamilton Cabral; Lewis J Greene; Eloiza H Tajara; J Silvio Gutkind; Carlos Curti; Andréia M Leopoldino
Journal:  Mol Cancer       Date:  2014-02-20       Impact factor: 27.401

10.  Pharmacological activation of NQO1 increases NAD⁺ levels and attenuates cisplatin-mediated acute kidney injury in mice.

Authors:  Gi-Su Oh; Hyung-Jin Kim; Jae-Hyuck Choi; Aihua Shen; Seong-Kyu Choe; Anzani Karna; Seung Hoon Lee; Hyang-Jeong Jo; Sei-Hoon Yang; Tae Hwan Kwak; Chul-Ho Lee; Raekil Park; Hong-Seob So
Journal:  Kidney Int       Date:  2013-09-11       Impact factor: 18.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.